Cabinet Medical Individual Diabet, Nutritie, Boli Metabolice Dr. Pop Lavinia
- Address
- lock Available on a paid plan
Diabetes and Metabolic Disease Research
Clinical research at Cabinet Medical Individual Diabet, Nutritie, Boli Metabolice Dr. Pop Lavinia focuses on Diabetes and Nutritional and Metabolic Diseases, with particular attention to Type 2 Diabetes and related metabolic conditions. The studies are centered on evaluating whether newer treatment options can improve blood sugar control and overall disease management.
- Assessing a new therapy approach for adults with Type 2 Diabetes
- Comparing treatment strategies to improve HbA1c outcomes
- Exploring better ways to manage long-term metabolic health
This research reflects a strong interest in practical treatment improvement for people living with diabetes, with the goal of finding more effective options for routine care.
Obesity and Weight-Related Health Studies
The site also conducts trials in Hormonal diseases and Nutritional and Metabolic Diseases related to Obesity and Overweight. These studies aim to understand whether new therapies can reduce health risks linked to excess body weight and improve broader clinical outcomes.
- Testing a treatment intended to support healthier weight-related outcomes
- Evaluating whether a new approach can reduce morbidity and mortality
- Advancing care for adults affected by Obesity
At this Romania-based clinic, the research emphasis is on therapies that may offer meaningful benefits beyond weight reduction, including better long-term health protection.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Eli Lilly & Co.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cabinet Medical Individual Diabet, Nutritie, Boli Metabolice Dr. Pop Lavinia
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2023-06-07 | 2024-02-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.